Reading Time: 2 minutesIntroduction Obesity remains a significant health concern in the United States, particularly among American males, where it contributes to a range of chronic conditions including cardiovascular disease, diabetes, and certain cancers. In the pursuit of effective weight management strategies, sermorelin, a synthetic analog of growth hormone-releasing hormone (GHRH), has emerged as a potential therapeutic agent. This article delves into a recent randomized clinical trial that explored the impact of sermorelin on reducing fat mass in overweight American males, offering insights into its long-term efficacy and safety. Study Design and Methodology The study was a randomized, double-blind, placebo-controlled trial involving 120 … Continue reading →